Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Columnists

About George S. Mack

George S. Mack
George S. Mack, Life Sciences Report

George S. Mack's Most Recent Articles

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital HLTH, CXV, PHM

George S. Mack | December 23, 2015
ETF

An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos

George S. Mack | December 16, 2015

Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap Consulting

George S. Mack | December 16, 2015

Regenerative Medicine Follows the CAR T-Cell Gravy Train: Maxim Group's Jason Kolbert and Jason...

George S. Mack | December 3, 2015

Oppenheimer's Rohit Vanjani: Finding Profit in the Generic Drug Pricing Wars

George S. Mack | November 18, 2015

How to Engineer a Strong Portfolio with Medtech and Biotech: Anita Dushyanth of Zacks Small-Cap...

George S. Mack | November 17, 2015

Raymond James Analyst Reni Benjamin: Regenerating Portfolios with Cell Therapies, Antibodies and...

George S. Mack | November 16, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack | September 3, 2015

Novel technology platforms with dramatic growth potential: Wedbush's David Nierengarten

George S. Mack | August 26, 2015

Acquisitions power growth of companies and portfolios: StoneCastle's Bruce Campbell

George S. Mack | August 20, 2015
1 2 Next